Trial · NCT06322953
Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage
NCT06322953, Phase 3, Recruiting, Walton Centre NHS Foundation Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage. Trials, record NCT06322953. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06322953
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage
- NCT number
- NCT06322953
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 1,084 participants, estimated
- Lead sponsor
- Walton Centre NHS Foundation Trust
- Conditions
- Traumatic Intracranial Haemorrhage
- Interventions
- Direct-Acting Oral Anticoagulants (used as per local standard practice)
- First posted
- 2024-03-21
- Last updated
- 2026-06-18
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients with haemorrhagic or thrombotic event within 12 weeks following tICrH. | 12 weeks | The total number of patients that have a haemorrhagic or thrombotic event within 12 weeks following tICrH. |
| Secondary | Time to first haemorrhagic or thrombotic event. | 12 weeks | Time to first haemorrhagic or thrombotic event. |
| Secondary | Time to first haemorrhagic event | 12 weeks | Time to first haemorrhagic event |
| Secondary | Time to first thrombotic event | 12 weeks | Time to first thrombotic event |
| Secondary | Time to death | 12 and 26 weeks | Time to death |
| Secondary | Functional outcome measured using modified Rankin Scale (mRS) | 26 weeks | The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale ranges from 0-6 with 0 being no symptoms and 6 being dead. |
| Secondary | Functional outcome measured using Barthel Index | 26 weeks | The barthel index is a tool to rank the patient's independence in 10 areas of daily living, such as feeding, bathing, dressing, and mobility. The total score ranges from 0-100 with 0 having no independence and 100 being totally independent. |
| Secondary | Functional outcome measured using extended Glasgow Outcome Scale (GOS-E) | 26 weeks | The scale runs from 0-6, running from perfect health without symptoms to death. The Extended Glasgow Coma Scale (EGCS) expands upon the traditional GCS by adding additional components to provide a more comprehensive assessment of a patient's neurological status. It consists of 8 levels with 1 being dead and 8 meaning patient has made a complete recovery. |
| Secondary | Functional outcome measured using Rockwood Frailty Score | 26 weeks | The Rockwood Clinical Frailty Scale is a tool used to assess a patient's overall level of frailty based on their physical fitness, comorbidities, and ability to perform daily activities. It classifies patients into 9 categories, ranging from 1 (very fit) to 9 (terminally ill), with higher scores indicating greater frailty and vulnerability to adverse health outcomes. |
| Secondary | Overall Quality of Life measured by EuroQol 5 Dimensions 5 Levels (EQ5D5L) questionnaire | 12 and 26 weeks | The EuroQol 5 Dimensions 5 Levels (EQ5D5L) is a standardized instrument used for measuring generic health status and health-related quality of life. This system comprises five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels of severity, ranging from no problems to extreme problems. In addition to the descriptive system, the EQ5D5L includes a vertical visual analogue scale (VAS) where respondents rate their current health on a scale from 0 to 100, with 0 representing the worst imaginable health state and 100 representing the best imaginable health state. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42754280 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06322953
GET https://conductscience.org/api/trials/v1/NCT06322953/registered